Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
We determined the susceptibility to antiviral drugs of clinical isolates of human immunodeficiency virus type 1 (HIV-1) subtypes A, B, C, D, and E. Isolates from treated and untreated patients were tested for sensitivity to zidovudine (ZDV), lamivudine (3TC), didanosine (ddI), nevirapine (NVP), foscarnet (PFA), and ritonavir (RNV). The susceptibility to these different drugs was broadly similar between the different subtypes of HIV-1. Isolates of subtype D showed a tendency toward slightly lower susceptibility to all the antiviral drugs, which could be related to the rapid growth characteristics of these isolates.
Palmer
S
S
Department of Virology, Swedish Institute for Infectious Disease Control, Karolinska Institute, Stockholm.
Alaeus
A
A
Albert
J
J
Cox
S
S
D019380:Anti-HIV Agents / Q000494:pharmacology*; D002461:Cell Line, Transformed; D002478:Cells, Cultured; D016049:Didanosine / Q000494:pharmacology; D017245:Foscarnet / Q000494:pharmacology; D015658:HIV Infections / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000166:cytology; D019829:Nevirapine / Q000494:pharmacology; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D019438:Ritonavir / Q000494:pharmacology*; D015215:Zidovudine / Q000494:pharmacology
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D017245:Foscarnet; D015215:Zidovudine; D019829:Nevirapine; D016049:Didanosine; D019438:Ritonavir